跳至主要内容
临床试验/NCT03380611
NCT03380611已完成不适用

Effects of Wakame and Spirulina Consumption on Intestinal Cholesterol Absorption in Non- Hypercholesterolemic Men and Women

Maastricht University Medical Center2 个研究点 分布在 1 个国家目标入组 36 人开始时间: 2017年10月24日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
36
试验地点
2
主要终点
Markers for intestinal cholesterol absorption

研究概览

简要总结

The primary objective of this study is to investigate the effects of wakame and spirulina consumption on intestinal cholesterol absorption.

详细描述

Objectives:

Secondary objectives are to investigate the effects of wakame and spirulina consumption on fasting markers for lipid metabolism, glucose metabolism and blood pressure.

Study design:

This study is a double-blinded, randomized, placebo-controlled, crossover intervention trial consisting of three intervention periods of 17 days each, separated by a minimum washout period of 14 days.

Study population:

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Prevention
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Aged between 18 and 70 years;
  • BMI between 18 and 30 kg/m2;
  • Non-smoking;
  • No elevated serum triacylglycerol concentrations (< 4.5 mmol/L);
  • Willing to comply to the study protocol during the study;
  • Agreeing to be informed about medically relevant personal test-results.

排除标准

  • Not willing to abstain from any algae and/or seaweed consumption or algae/seaweed containing products two weeks before the start and during the trial;
  • Use of plant-sterol/stanol-enriched foods (e.g. Becel Proactive) or supplements in the four weeks prior to the screening and/or during the study;
  • Use of cholesterol or lipid-lowering medications (e.g. statins, bile-acid sequestrates, cholesterol absorption inhibitors);
  • Use of any kind of medication or a medically prescribed diet, which can interfere with the study;
  • Use of oral antibiotics in 40 days or less prior to the start of the study;
  • Use of food supplements that might interfere with study measurements (judged by the principal investigator) in four weeks or less prior to the start of the study;
  • Indications of treatment according to the Standard for Cardiovascular Risk Management from the Dutch General Practitioners community;
  • Any medical condition that might interfere with study (measurements), judged by the principal investigator, including cardiovascular diseases or events (e.g. acute myocardial infarction or cerebro-vascular accident), diabetes, asthma, COPD, rheumatoid arthritis, and gastro-intestinal diseases (e.g. inflammatory bowel disease);
  • Unstable body weight (weight gain or loss > 3 kg in the past 3 months);
  • Females who are pregnant, breast feeding or who may wish to become pregnant during the study;
  • Consumption of > 14 (males) or > 10 (females) alcoholic consumptions a week;
  • Reported intense sporting activities > 10 hours a week;
  • • Abuse of drugs;
  • Participation in any other biomedical trial four weeks prior to the screening visit;
  • Having donated >150 ml blood within 1 month prior to the screening visit, planning to donate blood during the study or within one month after finishing the study;
  • Impossible or difficult to puncture as evidenced during the screening visit.

结局指标

主要结局

Markers for intestinal cholesterol absorption

时间窗: Difference in outcomes between interventions and control at 17 days

Serum cholesterol-standardized campesterol concentrations will be measured as a marker for intestinal cholesterol absorption

次要结局

  • Markers for cholesterol synthesis(Difference in outcomes between interventions and control at 17 days)
  • Blood pressure(Difference in outcomes between interventions and control at 17 days)
  • Lipids(Difference in outcomes between interventions and control at 17 days)
  • Glucose concentrations(Difference in outcomes between interventions and control at 17 days)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验